Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin

  • U. B. Schaad
  • J. Wedgwood-Krucko
  • K. Guenin
  • U. Buehlmann
  • R. Kraemer
Article

Abstract

In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks. Fifty-six cases of acute pulmonary exacerbation of the disease in 42 patients associated with isolation ofPseudomonas aeruginosa from the sputum were randomly treated with either aztreonam or ceftazidime (300mg/kg/day i.v.; maximum daily dose 12g) in combination with amikacin (36 mg/kg/day i.v.; maximum daily dose 1,500mg). Other aspects of the two-week treatment were constant. The two therapy groups were comparable in all respects. Both regimens were well tolerated and resulted in similar improvements in clinical, bacteriologic, radiologic and laboratory findings, and pulmonary function. Fifty patients could be reevaluated after subsequent outpatient therapy consisting of oral ciprofloxacin (30 mg/kg/day; maximum daily dose 1,500mg) given for four weeks. During this period, the clinical and laboratory improvements persisted, and the rate of eradication ofPseudomonas aeruginosa from sputum decreased from 62% to 34%. Ciprofloxacin was well tolerated and there was no drug toxicity or serious adverse effect. In the 25 prepubertal patients there was neither subjective nor objective evidence of skeletal drug toxicity. In patients with cystic fibrosis, aztreonam or ceftazidime in combination with amikacin represents an effective and safe systemic anti-pseudomonal therapy. Subsequent oral ciprofloxacin therapy for four weeks prolongs the beneficial effects and is well tolerated.

Keywords

Cystic Fibrosis Ceftazidime Amikacin Drug Toxicity Aztreonam 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Høiby, N., Friis, B., Jensen, K., Koch, C., Moller, N. E., Stovring, S., Szaff, M.: Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatrica Scandinavica 1982, Supplement 301: 75–100.Google Scholar
  2. 2.
    Marks, M. I.: The pathogenesis and treatment of pulmonary infectious in patients with cystic fibrosis. Journal of Pediatrics 1981, 98: 173–179.PubMedGoogle Scholar
  3. 3.
    Gold, R., Carpenter, S., Heurter, H., Corey, M., Levison, H.: Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1987, 111: 907–913.PubMedGoogle Scholar
  4. 4.
    Nelson, J. D.: Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. Journal of Pediatrics 1985, 106: 1030–1033.PubMedGoogle Scholar
  5. 5.
    Hyatt, A. C., Chipps, B. E., Kumor, K. M., Mellits, E. D., Lietman, P. S., Rosenstein, B. J.: A double-blind controlled trial of anti-pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1981, 99: 307–311.PubMedGoogle Scholar
  6. 6.
    Smith, A. L.: Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. Journal of Pediatrics 1986, 108: 866–870.PubMedGoogle Scholar
  7. 7.
    Wientzen, R., Prestidge, C. B., Kramer, R. I., McCracken, G. H., Nelson, J. D.: Acute pulmonary exacerbations in cystic fibrosis: a double-blind trial of tobramycin and placebo therapy. American Journal of Diseases in Children 1980, 134: 1134–1138.Google Scholar
  8. 8.
    Moss, R. B., Babin, S., Hsu, Y.-P., Blessing-Moore, J., Lewiston, N. J.: Allergy to semisynthetic penicillins in cystic fibrosis. Journal of Pediatrics 1984, 104: 460–466.PubMedGoogle Scholar
  9. 9.
    Adkinson, N. F., Swabb, E. A., Sugerman, A. A.: Immunology of the monobactam aztreonam. Antimicrobial Agents and Chemotherapy 1984, 25: 93–97.PubMedGoogle Scholar
  10. 10.
    Saxon, A., Hassner, A., Swabb, E. A., Wheeler, B., Adkinson, N. F.: Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. Journal of Infectious Diseases 1984, 149: 16–22.PubMedGoogle Scholar
  11. 11.
    Jacobus, N. V., Ferreira, M. C., Barza, M.: In vitro activity of aztreonam, a monobactam antibiotic. Antimicrobial Agents and Chemotherapy 1982, 22: 832–838.PubMedGoogle Scholar
  12. 12.
    Bosso, J. A., Black, P. G., Matsen, J. M.: Efficacy of aztreonam in pulmonary exacerbations in cystic fibrosis. Pediatric Infectious Disease Journal 1987, 6: 393–397.PubMedGoogle Scholar
  13. 13.
    Bosso, J. A., Black, P. G.: Controlled trial of aztreonam versus tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatric Infectious Disease Journal 1988, 7: 171–176.PubMedGoogle Scholar
  14. 14.
    Schaad, U. B., Wedgwood-Krucko, J., Suter, S., Kraemer, R.: Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. Journal of Pediatrics 1987, 111: 599–605.PubMedGoogle Scholar
  15. 15.
    Hodson, M. E., Roberts, C. M., Butland, R. J. A., Smith, M. J., Batten, J. C.: Oral ciprofloxacin compared with conventional intravenous treatment forPseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987, i: 235–237.CrossRefGoogle Scholar
  16. 16.
    Jensen, T., Pedersen, S. S., Høiby, N., Koch, C.: Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987, 6: 618–622.PubMedGoogle Scholar
  17. 17.
    Smith, M. J., White, L. O., Bowyer, H., Willis, J., Hodson, M. E., Batten, J. C.: Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1986, 30: 614–616.PubMedGoogle Scholar
  18. 18.
    Kraemer, R., Ruedeberg, A., Kläy, M., Rossi, E.: Relationship between clinical conditions, radiographic findings and pulmonary functions in patients with cystic fibrosis. Helvetica Paediatrica Acta 1979, 34: 417–428.PubMedGoogle Scholar
  19. 19.
    Chrispin, A. R., Norman, A. P.: The systemic evaluation of the chest radiograph in cystic fibrosis. Pediatric Radiology 1974, 2: 101–106.CrossRefPubMedGoogle Scholar
  20. 20.
    Jones, R. N., Barry, A. L., Gavan, T. L., Washington, J. A.: Susceptibility tests: microdilution and macrodilution broth procedures. In: Lennette, E. H., Balows, A., Hausler, W. J., Shadomy, H. J. (ed.): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 972–977.Google Scholar
  21. 21.
    Schaad, U. B., Desgrandchamps, D., Kraemer, R.: Antimicrobial therapy of pseudomonas pulmonary exacerbations in cystic fibrosis. Acta Paediatrica Scandinavica 1986, 75: 128–138.PubMedGoogle Scholar
  22. 22.
    Kraemer, R., Meister, B., Schaad, U. B., Rossi, E.: Reversibility of lung function abnormalities in children with perennial asthma. Journal of Pediatrics 1983, 102: 347–350.PubMedGoogle Scholar
  23. 23.
    Szaff, M., Høiby, N., Flensborg, E. W.: Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronicPseudomonas aeruginosa infection. Acta Paediatrica Scandinavica 1983, 72: 651–657.PubMedGoogle Scholar
  24. 24.
    De Groot, R., Smith, A. L.: Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clinical Pharmacokinetics 1987, 13: 228–253.PubMedGoogle Scholar
  25. 25.
    Šcribner, R. K., Marks, M. I., Weber, A. H., Tarpay, M. M., Welch, D. F.: Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates ofPseudomonas aeruginosa from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1982, 21: 939–943.PubMedGoogle Scholar
  26. 26.
    Wolfson, J. S., Hooper, D. C.: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 1985, 28: 581–586.PubMedGoogle Scholar
  27. 27.
    Woolfrey, B. F., Fox, J. M. K., Quall, C. O., Lally, R. T.: Error rates associated with the use of recently proposed breakpoints for testingPseudomonas aeruginosa versus gentamicin, tobramycin, and amikacin by the standardized disk agar diffusion test. Antimicrobial Agents and Chemotherapy 1983, 24: 764–770.PubMedGoogle Scholar
  28. 28.
    Suter, S., Schaad, U. B., Tegner, H., Ohlsson, K., Desgrandchamps, D., Waldvogel, F. A.: Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment againstPseudomonas aeruginosa. Journal of Infectious Diseases 1986, 153: 902–909.PubMedGoogle Scholar
  29. 29.
    Suter, S., Schaad, U. B., Morgenthaler, J. J., Chevallier, I., Schnebli, H. P.: Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis. Journal of Infectious Diseases 1988, 158: 89–100.PubMedGoogle Scholar
  30. 30.
    Wolz, C., Kiosz, G., Olge, J. W., Vasil, M. L., Schaad, U. B., Botzenhart, K., Döring, G.:Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiology and Infectiology 1989, 102: 205–214.Google Scholar
  31. 31.
    Christ, W., Lehnert, T., Ulbrich, B.: Specific toxicologic aspects of the quinolones. Reviews of Infectious Diseases 1988, 10, Supplement 1: 141–146.Google Scholar
  32. 32.
    Schaad, U. B., Wedgwood-Krucko, J.: Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987, 15: 165–168.CrossRefPubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1989

Authors and Affiliations

  • U. B. Schaad
    • 1
  • J. Wedgwood-Krucko
    • 1
  • K. Guenin
    • 1
  • U. Buehlmann
    • 1
  • R. Kraemer
    • 1
  1. 1.Department of Pediatrics, InselspitalUniversity of BerneBerneSwitzerland

Personalised recommendations